NEWSROOM
Discover all the actions carried out by Jeito and all the partnerships that we set up day after day for the well-being of patients and medical progress.
In the headlines
Jeito Capital Makes Significant Investment in the Second Closing of Alveus Therapeutics’ Oversubscribed Series A, Bringing Total Financing to $197 Million
Proceeds from the financing will advance the Phase 2 clinical development of Alveus’ lead program ALV‑100 designed to deliver potent, durable weight loss and long‑term maintenance with improved tolerability. The financing will also support Investigational New Drug...
Download our White Paper
We are pleased to share with you our White Paper, which offers a deep dive into the evolving biopharma landscape and highlights the key trends shaping its future.
Find all our press releases
Jeito Capital co-leads $65 million Series A financing in EyeBio
Paris, France, 22 February 2022 – Jeito Capital (“Jeito”), a leading independent private equity...
JEITO CAPITAL becomes key investor in NMD Pharma as part of a €35 Million new financing
Jeito Capital selected European clinical stage biotech NMD Pharma, based in Denmark, as its 7th...
Jeito Capital co-leads $156million oversubscribed Series B financing in Quell Therapeutics
Quell Therapeutics is the world leader in developing engineered T-regulatory (Tregs) cell...
Jeito Capital portfolio company SparingVision announces strategic collaboration with Intellia Therapeutics
Partnership will allow SparingVision to develop novel genomic medicines for the treatment of...
Jeito Capital becomes Key Player in the Financing of Life Sciences in Europe with the Closing of Jeito I at €534 million ($630 million)
Oversubscribed Jeito I becomes the largest European fund dedicatedto the life sciences sector....
Jeito Capital’s Dr. Rafaèle Tordjman Appointed to Promote the French Biotech Ecosystem
The appointment of Dr. Tordjman was granted by French Ministers, Agnès Pannier-Runacher and...
Face to face
Meet Jeito
12-15
January
All day long
JPM Healthcare Conference 2026
Jeito will be present at the 44th JPM Healthcare Conference 2026, renowned as the largest and most influential healthcare investment symposium, attracting global industry leaders, Biotech companies, and members of the investment community, in San Francisco.